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11084-151 I Plafobt Glycopmteln IIMIla Receptor Inhibition 
I)urlng PTCA for Acute MI: A RetmIpective 
Anelylls of In Ho|pltal and One Yeer Outcome 
J/A, Grant,am, 0. ~ i ,  S,L Ko~¢ W, D.R. Holmes. Mayo Clin¢, 
Roc~,~f'gr, MN, USA 
myocardi~ !,':ff,,amaoel (AMI) and relasl~ n1~to~ of pmtifemtim m re, 
epomm to ~ r ~  (PTC/I), "r~ cunme mdy w~ d~l  fo ~t  t~ 
Itypoll~m ti~t I~t~ uI~ of al~i~imab as a~urcth~ lheflllpy 1o PTCA in AMI 
i~ e~_~t~l  wilh im!~vemm~ in ~ho~t ned i n~te  tram outcomes, 
~ A ~o~t  d ~1~ i~tieel~ was ~ id~n l i~  Imm 
Mayo C~ PTCA R~l i t~/~a~ for IL~dm~rY PTCA ~ AM! 
tw~m Jem~fy I(1(15 (!he fimt y~,~r ~im~ ~ e~¢~!~e} t~ August 
1997, FifytwO pati(m~ rp¢~M~l =d~¢iximab (0 .~ ff~.l(g bofLzll renewed by tO 
~,~mut~ ov~ 12 hour~) lind 240 did noL All patkmlzl n~,.-eiv~l tan~ 
da~l I ~ .  I n ~  ~ one ~r  met~ty, ~ i.larction, ard 
gra~ ~ compared by c~ e,~am a. ,W~ a-d !',am~eye~ 
Suneva~ ,  
~ene  characte~tics and mults am as ~lows: 
Na abmmtab AIX'mm~d~ P Vak.= 
Basekne 
EF 58% 49~= p - 005 
Mo~ 1~1% 58% p=0tB 
Death. ReML CASG 138% 58% p = o 17 
t ',feat 
Deaith 17.t% 5.B%, p ~ 005 
Rel~, CABG 2B.I~, 58% p -~ 005 
~ :  These data suggest a ~ effed on overag in hosptal 
and (me year ~ when alx'iximab B administered in a(~ditmn fo staedard 
therapy and PTCA for AMI. 
ho84-1521 Tim ~ Eer=t of ~ W ~ h  ASA 
out, h~ 'rhrombotyt~ Therapy in Acute 
Myocardial bthncUon 
D_ Fmimark, S. Behar, S. Matetslo/, M. Fe~nberg, H. Hod. FoHheARGAMt*2 
St,Joy Group: Neufetd Cardiac Research Instn'ute. Sheba Medical Center. 
TetHastmmer, lsrael 
The beneficial effect of ASPIRIN (ASA) administrabon, ak~ne o¢ m comb- 
nation with streplokinase, on mortality reduction dunng acute myocard~l 
in fa~ (AMI). was impressively elucidated in the ISIS-2 trial. However, un- 
like threml0olytm therapy, them is nc ~ for a ~ ~ effect of 
ASA on early mortality after AMI. We evaluated the effect of ip~ethmmbo~s 
adm~nistratmn ofASA in patienls (pts) troth AMI tn a nationwide study. Among 
1200 pts with AML hosptalized in ;ill operating CCUs ,n Israel. 339 (28%) 
received ASA pnor to thmmbelysis. The charactenstcs of pts pretreated w~h 
ASA and those who were not given As~nn before thrombotysm, was sin.,~r. 
Results: 
&forfahfy: l:~ethrembolyt,c Treatment wttfl ASA Odds ratio (95% Ct) 
Yes (n = 339) No (n = 861) 
7 day 2.5% 60% 0.35 (0.14-0.76) 
30 day 3.3% 7.3% 042 (0.1 ¢~-O.89) 
Conclusion: Pretreatment with ASA in pts treated with thrembolytic agents 
was found to be associated with a significant reduction of 7- and 30-day 
mortality after AMI. 
11084-1531 Evidence for Enrollment Selection Bias in Trials 
i ! of Primary Angiopiasty: Compadson of GUSTO 
lib and RAPPORT 
S.J. Brener, S.G. Ellis, J.E.B. Burchenal. S. Katz. M.B. Eflron. E.J. Topoi. 
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Cleveland. Ohio. USA 
Background: Abciximab may further enhance the advantage of pnma~y an- 
gioplasty (PTCA) over thrembolytic therapy for acute myocardial infarction 
(MI) with respect to death, and reML 
Methods: We compared two recently completed clinical studies (GUSTO 
lib and RAPPORT) with respect to death and reinfarction at 30 days. Pts 
with MI <12 hr. were randomized in RAPPORT to placebo (P, n = 24;?.} er 
al0ciximab (A, n = 241) as an adjunctive to PTCA, and in GUSTO lib to PTCA 
(n = 565) or t-PA (L, n = 573). 30-day death, reinfarction, and angiograms 
were independently analyzed at the same location. 
Results: PIs in all four groups were simd~r wlth ~ to age, LF~Oer, 
prosenling blood pressure and heart rate, RAPPORT IptS had a 
h~gh~r *nc ic~ 0t diabetes, hype~t(ms~,t, prmr MI and fevascUlartlat~on, 
non-anterior MI, and non-curt(tar smoking. 
RAPPORT GUSTO I~ 
P k FTCA I~ 
Tw, e ~o R~ 4 p, el 3913, r~! :],e I~, ~,~) 3 I~, 431 
0eath ;~,t%' 2,P~," S,~ 7,t~ 
I~M1 4.1% ~r~ 4,4% 6,5% 
TIMI I!( 85"~ 87% 73%' 
('p ,~ 0,0~) 
~ :  RAPPORT had an tme~Pectt~ly tow moetahty, vv~ch can 
not be eq~Jne¢t mirCy by ~ m t~=~,¢m ¢h~mctw~t~. of an- 
g iogra l~ rt~ul~, Urtmeasumd ~Nection ~ iS tikaly q~pone, ilge foe tr.s 
Thrombo!ye!e or  Aflgloplaety for Acute 
Myo~rdk l l  InhlrCtlon 
Tuesday, March 31, 1998, 9;00 a,m,-11:00 a,m, 
Georgia World Congress Center, West Exhibit Hall Level 
Presentation Hour:, 10:00 a,m,-11:00 a,m, 
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Ba~gnxnt The dinma u~tW of pertom~ adiunct~e PTCA Or ~ng to 
m~ove flow m vessels w~h 11MI Grade 2 Row ~towing thmmbelys~ has 
not been fu.y h'~t~ateCL 
Meffmds: In TIM1 10B pI-PA (n = 311) vs 30, 40, or 50 mg of TNK (n = 
528), TIMI Grede 2 FIO~ at gO m/~. was traatad in a nsn-randomumd fashion 
~th meoca~ manogente~t (MedMgt). PTCA ak~e. or ranting (Stent). There 
was no significant d~:=erence m lhe pm inten~ntol TIMI Frame Counts for 
pts. b~ wdh MedMgt vs. PTCA or Staflt (57.7 ± 20.6 (n = I09) vs 63.9 ± 
310 (n = 44), p = 02). 
Result.s: TIMI Grade 3 Flow was restored in 89.5% (34/38) of vessels while 
T1MI Grade 2 Row per=sled in 10.5% (4/38) treated w~th PTC/VStanting, 
after inten~en~on mean CTFC = 30.8 ± 26.8. Clincal outcomes are shown 
below (all p = NS): 
MedMg! PTCA of Sten! 
Death (In Hoe;p} 28% (3/109) 45% (Z,44} 
Death 130 (~ay) 2.8'% (3/107) 50% 12J40) 
Rect:~. MI (In H~)  7.3% (8/109) 9.1% (4/44) 
RecuT. MI (30 day) 87% (9/r04) 10.0% (4/40) 
Deafft;ReMI (30 flay) 11.2%(12/107) 10.0% (4/40) 
~ :  TCAistaflting may not offer a major advantage m dinI~ll 
outcomes over MedMgt. Larger randomized ftmls are needed to Mcefla~ 
the benefit (if any) of mechanical intewe~tmn over MedMgt for TIMI 2 Flow 
fo~lo~ng itlrombelym. 
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Follow-up 
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Despite extensive investigatmn, long-term angiogrsphic data on patients (pts) 
undergoing prima~j angioplasty (PTCA) or tflrombolysis for em,'olving my- 
ocardial infarction (MI). are lacking. Therefore. pts enrolled in the GUSTO fib 
PTCA substudy in two spanish centers undena,'ent clinical and ang~graph,: 
assessment at one year. A total of 123 pts (61 assigned to tPA and 62 
to PTCA) were entered. Baseline clinical charactertstica of the two treated 
groups did not differ from those of the general study. Clinical endpoints were 
death, reMI and need for revasoularization. One year clinical outcomes: 
Death re (MI)  rePTC/VCABG Total 
tPA 8 3 18 26 (43%) 
PTCA 8 '~ 7 15 (24%) 
p ns ns 0.01 003 
CABG = coronary artery byPasS graft. 
